Accurate Diagnosis of Non-alcoholic Steatohepatitis using Novel Protease Activity-based Liquid Biopsy

Time: 11:30 am
day: Post Conference Seminar Day


  • Transcriptomic analysis of human liver biopsies across 2 independent cohorts of NAFLD patients revealed that proteases are widely dysregulated in progressive NASH, and panels as few as 13 proteases have the capacity to discriminate F2+ from F0-F1 with high accuracy (AUC> 0.85).
  • Glympse has developed a plasma-based Glympse liquid biopsy (LBx)-NASH, a novel non-invasive method using fluorogenic protease activity biosensors to directly measure protease activity and predict NASH .
    * We tested LBx NASH in 76 human NASH and 12 control plasma samples, predicting NASH from healthy and obese controls with an AUC=0.97 (95% CI 0.93-1.00), independent of gender, age, obesity and type 2 diabetes.